Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ispinesib in Metastatic or Recurrent Malignant Melanoma
NCT00095953Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ispinesib in Malignant Melanoma (MM), sponsored by Canadian Cancer Trials Group. Primary endpoint: Response Rate at 2 years. Started Nov 2004; status: completed.
02
Drugs
ispinesib
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00095953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095953.